Thomas Uguen, MD

CIO 2023-13 IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab vs surveillance in hepatocellular carcinoma patients

Purpose: The risk of HCC recurrence after liver resection or ablation with curative intent is 70-80% within 5 years, indicating an unmet need for effective adjuvant therapies. Atezolizuma...

Jeong Heo , MD, PhD;

David Hsieh , MD;

Masatoshi Kudo , MD, PhD;

Han Chu Lee , MD, PhD;

Qinshu Lian , PhD;

Shinichiro Nakamura , MD, PhD;

Kazushi Numata , MD;

Shukui Qin , MD, PhD;

Jessica Spahn , PhD;

Won Young Tak , MD, PhD;

Thomas Uguen , MD;

Edward Cha , PhD;

Lu Wang , MD, PhD, MS;

Minshan Chen , MD, PhD;

Xiaoyu Wen , MD, PhD;

Ann-Lii Cheng , MD, PhD;

Chun Wu , PharmD;

Pierce Chow , MBBS, FRCS, PhD;

Adam Yopp , MD;

Stephen Hack , MBChB;

Jian Zhou , MD, PhD;

11/01/2023

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

April 30 ⁠–⁠ May 5

May 1 ⁠–⁠ May 3

May 19 ⁠–⁠ May 21

See Full Calendar

Thomas Uguen, MD

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products